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Abstract 24 
The angiotensin converting enzyme (ACE) and dipeptidyl peptidase-IV (DPP-IV) 25 
inhibitory activities of cross-linked and non-cross-linked NaCN hydrolysates were studied. Three 26 
different samples were generated: NaCN hydrolysed with Prolyve 1000™ (Prolyve), NaCN cross-27 
linked with transglutaminase (TGase) pre-Prolyve hydrolysis (TGase/Prolyve) and NaCN cross-28 
linked post-Prolyve hydrolysis (Prolyve/TGase). Gel filtration and reverse phase HPLC analysis 29 
of the resulting samples indicated that the hydrolysates had similar peptide profiles. Hydrolysates 30 
showed higher (p<0.05) ACE and DPP-IV inhibitory activity compared with intact protein but no 31 
significant (p>0.05) differences in activity were found between cross-linked and non-cross-linked 32 
hydrolysate samples. Hydrolysate IC50 values for ACE and DPP-IV inhibition ranged from 0.10-33 
0.17 mg mL-1 and 0.85-1.18 mg mL-1, respectively. Simulated gastrointestinal digestion had no 34 
significant (p>0.05) effect on the bioactivities of the hydrolysates. The results demonstrated that 35 
incubation with TGase before or after NaCN hydrolysis with Prolyve had no effect on ACE or 36 
DPP-IV inhibitory activities. 37 
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2.2. Introduction 47 
Enzymatic hydrolysis is a process used to modify the functional and physicochemica l 48 
properties of food proteins (Flanagan & FitzGerald, 2002; Spellman, Kenny, O'Cuinn, & 49 
FitzGerald, 2005). Furthermore, food proteins contain bioactive peptides in their primary 50 
structures that can be released during hydrolysis and may subsequently be used as biofunctiona l 51 
ingredients. Many studies have reported that caseins are rich in angiotensin converting enzyme 52 
(ACE) inhibitory peptides (Luo, Pan, & Zhong, 2014; Miguel, Contreras, Recio, & Aleixandre, 53 
2009; Norris & FitzGerald, 2013; Robert, Razaname, Mutter, & Juillerat, 2004). Furthermore, 54 
casein appears to be the milk protein substrate displaying the highest number of dipeptidyl 55 
peptidase-IV (DPP-IV) inhibitory peptide sequences (Lacroix & Li-Chan, 2012; Nongonierma & 56 
FitzGerald, 2013, 2015a; Power, Nongonierma, Jakeman, & FitzGerald, 2014). This may be 57 
linked, in part, to the high content of Pro residues in caseins, which is related with high DPP-IV 58 
and ACE inhibitory activities.  59 
Enzymatic cross-linking is also a widely used method of protein modification which results 60 
in the addition of inter- and intra-cross links within and between protein residues. 61 
Transglutaminase (TGase; E.C. 2.3.2.13) is an enzyme which can catalyse cross-linking reactions 62 
between the amino acids Lys and Gln in proteins leading to the formation of an isopeptide bond 63 
(Motoki & Seguro, 1998). The addition of TGase to sodium caseinate (NaCN) modified its 64 
structure, and enhanced its emulsifying and foaming properties. Moreover, the combination of 65 
cross-linking and enzymatic hydrolysis of NaCN resulted in a further significant improvement in 66 
the above mentioned properties (Flanagan, Gunning, & FitzGerald, 2003). However, there is 67 
limited information about the biofunctional activities of protein hydrolysates subjected to TGase 68 
treatment and some of the reports appear contradictory. Cross-linking of soy protein isolate 69 
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hydrolysates (Fan, et al., 2005) and soybean protein hydrolysates (Song, et al., 2013) was reported 70 
to have no effect on in vitro antioxidant activity. Similarly, Hiller and Lorenzen (2009) 71 
demonstrated that TGase did not modify the antioxidant activity of whey protein isolates and total 72 
milk proteins. However, a recent study from Bagheri, Madadlou, Yarmand, and Mousavi (2014) 73 
reported a significant (p<0.05) improvement in antioxidant activity of TGase cross-linked whey 74 
protein hydrolysates using the ferric reducing antioxidant power assay. The addition of TGase in 75 
combination with hydrolysis with the proteolytic enzyme Alcalase decreased the immunoreactivity 76 
of α-lactalbumin and β-lactoglobulin (Wróblewska, Jędrychowski, Hajós, & Szabó, 2008). 77 
However, O’Sullivan and FitzGerald (2012); Sabadin, Villas-Boas, Zollner, and Netto (2012); 78 
Stanic, et al. (2010), found no differences in antigenic properties between cross-linked and non-79 
cross-linked casein hydrolysates. Furthermore, O’Sullivan, Lahart, O’Callaghan, O’Brien, and 80 
FitzGerald (2013) showed that NaCN hydrolysate samples generated by cross-linking with TGase 81 
prior to enzymatic hydrolysis produced an anti-inflammatory response in Jurkat T cells, while 82 
TGase treatment following hydrolysis and non-cross-linked hydrolysates showed no response. 83 
Although it has been demonstrated that some NaCN hydrolysates may possess in vitro bioactivit ies 84 
(Nongonierma & FitzGerald, 2013; Wu, Pan, Zhen, & Cao, 2013) no studies appear to have yet 85 
reported on the effect of TGase cross-linking on in vitro markers related to glycaemic management 86 
and blood pressure effects, i.e., DPP-IV and ACE inhibitory activity, respectively.  87 
Given the limited information and the potentially contradictory results reported on the role 88 
of TGase treatments, the aim of the present study was to characterise the effect of combining cross-89 
linking and enzymatic hydrolysis on the physicochemical and in vitro ACE and DPP-IV inhibitory 90 
properties of NaCN. 91 
 92 
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2.3. Material and methods 93 
2.3.1. Materials 94 
NaCN (87.57 %, (w/w, protein)) was provided by Arrabawn Co-op Society Ltd., Tipperary, 95 
Ireland. Calcium independent TGase from Streptoverticillium spp. was provided by Forum 96 
Products Ltd. (Brighton Rd., Redhill, Surrey, England). Prolyve 1000™ was kindly provided by 97 
Lyven Enzymes Industrielles (Caen, France). Trinitrobenzensulphonic acid (TNBS) was from 98 
Medical Supply Company (Dublin, Ireland). HPLC grade water and acetonitrile and PTFE syringe 99 
ﬁlters (0.2 µm) were obtained from VWR International (Dublin, Ireland). Bovine lung for the 100 
extraction of ACE was provided by Gaelic Meats and Livestock Ltd. (Limerick, Ireland).  Abz-101 
Gly-p-nitro-Phe-Pro-OH and Abz-Gly-OH-HCl were from Bachem Feinchemikalien (Bubendorf, 102 
Switzerland). Black 96-well microplates were purchased from Thermo Fisher Scientiﬁc (Dublin, 103 
Ireland). Triﬂuoroacetic acid (TFA) and L-leucine were supplied by Sigma–Aldrich (Dublin, 104 
Ireland). All other chemicals were obtained from Sigma and were of analytical grade unless 105 
otherwise stated. 106 
 107 
2.3.2. Generation of cross-linked NaCN hydrolysates 108 
 A NaCN solution (10 % (w/v) protein) was incubated with 0.3 % (v/v) Prolyve 1000™ at 109 
50 ºC and pH 7.0 using a pH stat (Titrando 843, Metrohm, Dublin, Ireland) to generate the non-110 
cross-linked hydrolysates (termed Prolyve) . Prolyve 1000™ is a non-specific microbia l 111 
endoproteinase, produced by Bacillus licheniformis, which contains subtilisin activity (Spellman, 112 
O'Cuinn, & FitzGerald, 2009). Aliquots were taken at several time points. After 240 min of 113 
incubation, the enzymatic reaction was stopped by heating at 80 ºC for 20 min. For the production 114 
of the cross-linked post-hydrolysis samples (Prolyve/TGase), the hydrolysed sample (Prolyve) was 115 
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incubated with TGase (2% (w/v)) at room temperature and pH 7.0 for 180 min. Inactivation of 116 
TGase was carried out as mentioned above. For cross-linking pre-hydrolysis samples 117 
(TGase/Prolyve), NaCN was incubated first with TGase and subsequently submitted to hydrolys is 118 
with Prolyve 1000™ using the same conditions as outlined above. A NaCN solution (10 % (w/v) 119 
protein) incubated at 50 ºC for 240 min and subjected to the heat treatment conditions used for 120 
enzyme inactivation was used as a control (Intact NaCN) in all experiments. 121 
 122 
2.3.3. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 123 
SDS-PAGE was performed using a Mini-Protean® Tetra Cell system (Bio-Rad, Hemel 124 
Hempstead, UK) according to the method of Laemmli (1970) using Mini-PROTEAN TGX precast 125 
gels (4-20 % resolving gel). The quantity of protein added to each well was between 15-20 µg. 126 
The molecular mass of the proteins was estimated by reference to the relative migration of the 127 
molecular weight standards SigmaMarker™ Wide Range (M.W. 6,500-200,000). The gel was 128 
stained with a Coomassie Blue R-250 solution and destained in an aqueous solution of 40 % (v/v) 129 
methanol and 10 % (v/v) acetic acid. 130 
 131 
2.3.4. Determination of degree of hydrolysis (DH) 132 
The DH was determined using the TNBS method as outlined by Adler-Nissen (1979) using 133 
L-Leucine as standard. The percentage degree of hydrolysis was calculated using the formula as 134 
described previously by Spellman, et al. (2009). 135 
 136 
2.3.5. Gel filtration and reversed-phase high performance liquid chromatography 137 
Gel permeation high performance liquid chromatography (GP-HPLC) and analytica l 138 
reversed-phase (RP-) HPLC were performed as described previously by Spellman, et al. (2009) 139 
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with minor modifications. For GP-HPLC, 20 μL of sample (0.8 % (w/v)) was injected on a TSK 140 
G2000 SW separating column (600 × 7.5 mm ID). Separation was performed by isocratic elution 141 
using 0.1% (v/v) TFA, 30% (v/v) acetonitrile in H2O, at a flow rate of 1 mL min−1. For RP-HPLC 142 
samples (20 μL at 0.8% (w/v)) were injected on a Jupiter Proteo column (C18, 250 mm x 4.6 mm 143 
ID, 5 µm particle size, 300 Å pore size, Phenomenex, Cheshire, UK). The column was equilibrated 144 
using solvent A: 0.1 % (v/v) TFA in H2O at a flow rate of 1 mL min−1. Samples were eluted using 145 
solvent B: 0.1 % (v/v) TFA, 80 % acetonitrile (v/v) in H2O at a flow rate of 1 mL min−1 employing 146 
a linear gradient from 0% at 0 min to 100% at 60 min. 147 
 148 
2.3.6. ACE inhibitory activity 149 
 The ACE used was extracted from fresh bovine lung following the method by Meng, 150 
Balcells, Dell'Italia, Durand, and Oparil (1995). ACE inhibitory activity was measured using the 151 
fluorometric method of Sentandreu and Toldrá (2007) with some minor modifications. An aliquot 152 
(50 µL) of test sample was added to 50 µL of assay buffer (100 mM sodium borate buffer, 300 153 
mM NaCl, pH 8.3) and 200 µL of substrate (0.45 mM Abz-Gly-Phe-(NO2)-Pro). The reaction was 154 
started with the addition of 50 µL of enzyme extract (8 mU) and fluorescence was determined 155 
using a Synergy HT Multi-Mode Microplate Reader (BioTek, Mason Technology, Dublin, Ireland) 156 
for 30 min at excitation and emission wavelengths of 360 and 400 nm, respectively. Fluorescence 157 
from the release of product (Abz-Gly) was quantified at time zero and time 30 min. Experiments 158 
were carried out as independent triplicates assayed in triplicate. IC50 values (concentration of 159 
inhibitor that inhibits 50 % of ACE activity) were calculated using GraphPad® Prism 4.0 sigmo ida l 160 
dose response plots of inhibitor concentration (mg mL-1) versus % inhibition. The values were 161 
expressed as the mean IC50 ± standard deviation (n=3). Captopril was used as a reference positive 162 
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control. 163 
 164 
2.3.7. DPP-IV inhibitory activity 165 
DPP-IV inhibition was assayed by the method of Nongonierma and FitzGerald (2014a) 166 
with minor modifications. In brief, 10 μL of serial dilutions of protein hydrolysate (5-0.05 mg mL-167 
1) was mixed with 30 μL 20 mM Tris–HCl buffer, pH 8.0 containing 100 mM NaCl and 1 mM 168 
EDTA, and 50 μL 200 μM H-Gly-Pro-AMC. Following 5 min incubation at 37 °C the reaction was 169 
initiated by addition of 10 μL DPP-IV (8 mU mL− 1). The change in fluorescence was monitored 170 
over a 30 min period using a plate reader Varioskan Flash (ThermoScientific, Tewksbury, MA, 171 
USA) at excitation and emission wavelengths of 360 and 460 nm, respectively. One unit (U) of 172 
DPP-IV activity was defined as that amount of enzyme which hydrolyses 1 μmol of H-Gly-Pro-173 
AMC per min at 37 °C. Diprotin A was used as a reference DPP-IV inhibitory substance. The 174 
inhibition was expressed as IC50 values. IC50 values are reported as the mean of three independent 175 
replicate assays ± standard deviation. 176 
 177 
2.3.8. In vitro simulated gastrointestinal digestion 178 
The two stage digestion process was performed according to the method of Walsh, et al. 179 
(2004). For gastric digestion, the Prolyve, Prolyve/TGase and TGase/Prolyve samples were 180 
incubated with pepsin (enzyme:substrate ratio 1:40 (w/w)) for 1.5 h at 37ºC and pH 2.0 followed 181 
by intestinal digestion with Corolase PP® (enzyme:substrate ratio 1:10 (w/w)) for 3 h  at 37 ºC and 182 
pH 7.0. Both enzymes were inactivated by heating the sample at 80 ºC for 20 min. Aliquots of the 183 
samples were taken at several time points. The DH, ACE and DPP-IV inhibitory activities of the 184 
digested samples were performed as mentioned above.  185 
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 187 
2.3.9. Statistical analysis 188 
Data were reported as means ± standard deviation of three independent replicates. ANOVA 189 
one way analysis of variance with Bonferroni or Dunnett test was used to analyse the results using 190 
Graphpad Prism, version 4.00 for Windows. Significant levels were defined as p < 0.05. 191 
 192 
 193 
2.4. Results and discussion  194 
2.4.1. Characterisation of the hydrolysates 195 
 Three different samples were generated in the present study. NaCN cross-linked pre-196 
hydrolysis (TGase/Prolyve), NaCN cross-linked post-hydrolysis (Prolyve/TGase) and NaCN 197 
hydrolysed with Prolyve 1000™ (Prolyve). Figure 1A shows the SDS-PAGE profile of NaCN 198 
incubated with TGase. After 30 min of incubation (Fig 1A, lane 3), the profile showed the 199 
appearance of bands with higher molecular masses in the 65 kDa region and a decrease in the 200 
intensity of the casein bands (24-30 kDa region) suggesting that polymerization occurred. 201 
Following 180 min of incubation with TGase (Fig 1A lane 8), reductions in the intensity of the 202 
casein bands were evident with higher molecular bands appearing around 220 kDa. Furthermore, 203 
at the later stages of TGase incubation (120-180 min, Fig 1A lanes 6-8) it was evident that large 204 
molecular mass polymers were present which do not enter the gel. Figure 1B represents the SDS-205 
PAGE profile of NaCN incubated with the proteolytic enzyme Prolyve. The NaCN control (Fig 206 
1B lane 2) shows bands representing α- , β- and κ-casein, eluting at 34, 29 and 24 kDa, respectively. 207 
After 5 min of hydrolysis (Fig 1B lane 3) the caseins were degraded and low molecular weight 208 
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bands appeared on the gel. After 180 and 240 min of hydrolysis (Fig 1B lanes 8,9) no bands were 209 
detected in the gel indicating that the molecular masses of the peptides in the samples were less 210 
than 6 kDa. Figure 2 a and b shows the molecular mass distribution profile, obtained by GPC-211 
HPLC, and the DH (%) as a function of time during incubation with TGase and Prolyve. As 212 
expected, the addition of TGase prior to or after hydrolysis did not alter the DH of the cross-linked 213 
samples, whereas the addition of Prolyve increased the extent of hydrolysis and therefore the 214 
release of peptides from NaCN. At the end of the hydrolysis process, 90 % of the samples were < 215 
2 kDa and the DH obtained for the three samples, Prolyve, TGase/Prolyve and Prolyve/TGase 216 
reached similar (p>0.05) values, i.e. 17.4 ± 0.4, 16.7 ± 0.7 and 16.9±0.5%, respectively (Table 1). 217 
The RP-HPLC profiles (Figure 3) showed no discernable differences in the peptide profiles 218 
obtained for the Prolyve, TGase/Prolyve and Prolyve/TGase samples. O’Sullivan, et al. (2013) 219 
previously reported that the profiles of similar NaCN hydrolysates showed some residual intact 220 
protein (at ~53 min) in the Prolyve sample that did not appear in Prolyve/TGase and TGase/Prolyve 221 
samples. However, in this study a minor peak of intact NaCN at ~53 min was seen in all the cross-222 
linked and non-cross-linked samples (Fig.3). It was previously reported that TGase treatment after 223 
hydrolysis of β-lactoglobulin resulted in a lower DH in comparison to the non-treated hydrolysates 224 
indicating that polymerization had occurred (Sabadin, et al., 2012). In contrast, the results found 225 
in this study showed a lower final mean DH value for the cross-linked samples compared to the 226 
non-cross-linked sample, however, these values were not significantly (p>0.05) different. The 227 
differences in the results observed between these studies could be attributed to the study 228 
differences, e.g., protein substrate, proteolytic preparation and the concentration of TGase used. 229 
Overall, the results found herein show that no major differences were detectable in the 230 
physicochemical properties (SDS-PAGE, % DH, RP- and GP-HPLC profiles) of the hydrolysates 231 
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produced regardless of the order of cross-linking, i.e., prior to or after hydrolysis. These findings 232 
concur with those of (O’Sullivan & FitzGerald, 2012) which reported no differences in 233 
physicochemical properties between samples hydrolysed pre or post TGase cross-linking. 234 
 235 
2.4.2. In vitro simulated gastrointestinal digestion (SGID) 236 
The ability of bioactive peptides to exert their function may depend on their resistance to 237 
digestion by gastrointestinal enzymes and to their capability to pass through the intestinal barrier 238 
in order to reach target organs (Segura-Campos, Chel-Guerrero, Betancur-Ancona, & Hernandez-239 
Escalante, 2011). An in vitro study with digestive enzymes was performed herein with the aim of 240 
evaluating the stability of the cross-linked NaCN hydrolysates to gastrointestinal digestion. This 241 
two stage process was performed using pepsin and Corolase PP® as gastric and pancreatic enzyme 242 
preparations, respectively. The extent of hydrolysis obtained after the two stages of the SGID 243 
process is shown in Figure 4. As mentioned previously, the Prolyve, TGase/Prolyve and 244 
Prolyve/TGase samples had a DH of ~17 %. After incubation with pepsin there was a small 245 
increase in the DH (from 0.0 h to 1.5 h). However, incubation with Corolase PP® produced a 246 
significant increase (p<0.05) in the extent of hydrolysis (from 1.5 h to 4.5 h) reaching values of 247 
31.4 ± 5.2, 31.6 ± 6.2 and 33.4 ± 4.2 % DH for Prolyve, TGase/Prolyve and Prolyve/TGase, 248 
respectively (Figure 4 and Table 1). Pepsin is an aspartic proteinase with broad substrate specific ity 249 
(Vance, LeBlanc, & London, 1997) and Corolase PP® is a porcine proteolytic preparation of 250 
pancreatic enzymes with broad specificity and activities (e.g., trypsin, chymotrypsin, elastase and 251 
carboxypeptidase) (Mullally, O'Callaghan, FitzGerald, Donnelly, & Dalton, 1994). This may 252 
explain the further hydrolysis observed after SGID treatment. This change was also observed in 253 
the RP-HPLC profiles as shown in Fig. 3 a, b and c. Hydrolysates appeared to be resistant to pepsin 254 
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digestion and no major changes were observed in the chromatographic profiles in comparison with 255 
the non-SGID samples. Following incubation with Corolase PP®, the samples displayed further 256 
hydrolysis where more hydrophilic peptides were generated. The same trend has been found in 257 
other studies such as by Guo, et al. (2015) who reported a small increase in DH after incubatio n 258 
of Alaska Pollock skin collagen with pepsin and a large increase in DH when the sample was 259 
incubated with Corolase PP®.  The RP-HPLC profile of the samples before and after incubation 260 
with Corolase PP® showed minor differences between the samples (Fig.3 a, b and c). The results 261 
herein demonstrate that no significant comparable differences in DH (p>0.05) or gross peptide 262 
profile were observed between the cross-linked and non-cross-linked samples following SGID.  263 
 264 
2.4.3 ACE and DPP-IV inhibitory activity  265 
  ACE is a carboxydipeptidase which plays a major role in the regulation of blood pressure 266 
by activation of the renin-angiotensin-aldosterone system. It catalyses the conversion of 267 
angiotensin I into the vasoconstrictor, angiotensin II. Some peptides with hypotensive properties 268 
act as natural inhibitors of ACE (FitzGerald, Murray, & Walsh, 2004). The different hydrolysates 269 
and associated control sample were tested for their ACE inhibitory activity and the results are 270 
summarised in Table 1.  The IC50 for Captopril, the positive control, was 3.5 ngmL-1, this concurs 271 
with the values reported elsewhere in the literature. As expected, unhydrolysed NaCN had a high 272 
ACE IC50 value (>10 mg mL-1) which indicates that the parent protein had minimal inhibitory 273 
activity. NaCN hydrolysis with Prolyve showed the highest mean inhibitory activity (IC50 = 0.10 274 
± 0.02 mg mL-1) followed by Prolyve/TGase and TGase/Prolyve with IC50 = 0.15 ± 0.04 mg mL-1  275 
and IC50 = 0.17 ± 0.05 mg mL-1, respectively. However, TGase cross-linking before and after 276 
hydrolysis had no significant effect (p>0.05) on ACE inhibitory activity. After SGID the mean 277 
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TGase/Prolyve IC50 value decreased while that of Prolyve/TGase increased. However, the changes 278 
were not significantly (p>0.05) different. ANOVA analysis showed no significant differences 279 
between the hydrolysates, whereas all hydrolysates were different from the control. The ACE IC50 280 
values for the hydrolysates observed in this study are similar to those of Hayes, et al. (2007), i.e., 281 
0.8 mg mL-1 for bovine casein fermentates generated with Lactobacillus animalis and were lower 282 
than those reported by Wu, et al. (2013), (2.36 mg mL-1) in bovine casein fermentates obtained 283 
with Lactobacillus casei. The ACE inhibitory activity of a hydrolysate depends on the type of 284 
proteinase and the protein used as the substrate (Xie, Kim, Ha, Choung, & Choi, 2014). Connolly, 285 
Piggott, and FitzGerald (2014) reported that Prolyve and Alcalase were the enzymes that yielded 286 
the most potent ACE inhibitory hydrolysates in brewers’ spent grain (BSG) protein hydrolysates. 287 
This was probably due to the broad specificity of the enzymes compared with other proteolytic 288 
preparations tested such as Flavourzyme, Protamex or Promod. Prolyve and Alcalase, obtained 289 
from Bacillus licheniformis, have subtilisin activity but only Alcalase possesses an additiona l 290 
minor glutamyl endopeptidase activity (Spellman, et al., 2005).  The results show that potent in 291 
vitro SGID resistant ACE inhibitory hydrolysates can be generated from NaCN using Prolyve; 292 
furthermore, the cross-linking treatment has no effect on the activity.  293 
 DPP-IV is a peptidase that regulates the degradation of GLP-1 and GIP, incretins that 294 
activate the release of insulin from the pancreas to the circulation. Casein hydrolysates have been 295 
associated with DPP-IV inhibitory properties (Nongonierma & FitzGerald, 2013).  However, to 296 
the best of our knowledge, there appears to be no information in the literature in relation to the 297 
inhibition of DPP-IV by cross-linked casein hydrolysates. The DPP-IV inhibitory activity of the 298 
NaCN hydrolysates generated herein was therefore investigated. The results obtained are 299 
summarised in Table 1. The IC50 for diprotin A, the positive control, was 1.2 µg mL-1, this value 300 
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concurs with those reported elsewhere in the literature. Hydrolysis of NaCN released potent DPP-301 
IV inhibitory hydrolysates with IC50 values of 1.20 ± 0.13, 1.05 ± 0.20 and 0.97 ± 0.18 mg mL-1  302 
for Prolyve, TGase/Prolyve and Prolyve/TGase, respectively, whereas the parent protein was not 303 
able to inhibit DPP-IV. The DPP-IV inhibitory values obtained in this study were within the same 304 
range to those reported previously for casein hydrolysates (0.88-1.11 mg mL-1, Nongonierma and 305 
FitzGerald (2013)). However, as observed with the results for ACE inhibitory activity, no 306 
significant differences (p>0.05) were found between the three different sets of samples. 307 
Furthermore, while SGID decreased the mean IC50 values, no significant (p>0.05) differences were 308 
found compared to the non-SGID samples. These results indicate that the peptides responsible for 309 
the DPP-IV inhibitory activity are stable to SGID enzymes. These results are very similar to those 310 
reported by Nongonierma and FitzGerald (2015b), in plant based derived hydrolysates, where no 311 
significant differences on DPP-IV activity were shown before and after SGID treatment. The lack 312 
of significant differences in bioactivity following SGID may be the result of two different events. 313 
SGID treatment (a) had no effect on those peptides responsible for DPP-IV inhibition or 314 
alternatively (b) SGID treatment resulted in the degradation of DPP-IV inhibitory peptides and the 315 
release of new inhibitory sequences. A similar outcome may have arisen for the ACE inhibitory 316 
activity following SGID treatment. The inhibitory potencies of the hydrolysates for ACE and DPP-317 
IV were significantly lower than that of synthetic drugs such as Captopril or the synthetic peptide 318 
diprotin A. However, the use of naturally derived ACE and DPP-IV inhibitors has the advantage 319 
of not presenting the side-effects associated with synthetic drug inhibitory compounds. 320 
The bioactivities of the hydrolysates are directly related with their primary structure. It is 321 
well known that NaCN is rich in the hydrophobic amino acid Pro which is correlated with peptides 322 
displaying high DPP-IV and ACE inhibitory activities (Nongonierma & FitzGerald, 2014b; Norris 323 
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& FitzGerald, 2013). Some studies suggest that the use of TGase prior to or after hydrolysis of 324 
NaCN could modify the structure of the parent protein and therefore lead to the generation of new 325 
bioactive peptide entities. However, in the present study it appears that the potent ACE and DPP-326 
IV bioactive hydrolysates obtained are a result of the hydrolysis process rather than due to cross-327 
linking. 328 
 329 
 330 
2.5. Conclusion 331 
The results reported herein showed that minor differences were found in the 332 
physicochemical properties of TGase cross-linked and non-cross-linked NaCN Prolyve 333 
hydrolysates. TGase cross-linked and non-cross-linked NaCN hydrolysates had significantly 334 
higher DPP-IV and ACE inhibitory activity in comparison to intact NaCN. However, no significant 335 
differences in in vitro bioactivities were observed between cross-linked and non-cross-linked 336 
hydrolysates. The effects of TGase cross-linking and hydrolysis with other proteolytic enzyme 337 
preparations on the in vitro bioactivites is a yet unknown. Furthermore, the in vitro bioactivities of 338 
the TGase cross-linked Prolyve hydrolysates were maintained following SGID. This indicates that 339 
TGase cross-linking had no effect on the overall bioactivity of the Prolyve hydrolysates. Analys is 340 
of the peptide sequences within the different hydrolysates should help further elucidate the 341 
structural differences between the cross-linked hydrolysates. Previous analysis of the hydrolysates 342 
demonstrated no effect of the order of cross-linking on hydrolysate antioxidant properties 343 
(Cermeño, FitzGerald, & O'Brien, 2016). However, the non-cross-linked Prolyve NaCN 344 
hydrolysate was shown to have a DNA protective effect against H2O2 induced U937 cells when 345 
grown in culture, an effect not observed with the TGase cross-linked hydrolysate samples. These 346 
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results indicate that the effects of cross-linking may be dependent on the biomarker being analysed.  347 
 348 
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FIGURE CAPTIONS  473 
Figure 1. (A) Sodium dodecyl sulphate polyacrylamide gel electrophoresis  (SDS-PAGE) profile of sodium caseinate 474 
(NaCN) incubated with transglutaminase (TGase, 2 % (w/v)) for different durations. Lane 1, Wide range molecular 475 
weight marker; Lane 2, Intact NaCN; Lane 3, NaCN incubated with TGase for 30 min; Lane 4, NaCN incubated with 476 
TGase for 60 min; Lane 5, NaCN incubated with TGase for 90 min; Lane 6, NaCN incubated with TGase for 120 min;  477 
Lane 7, NaCN incubated with TGase for 150 min; Lane 8, NaCN incubated with TGase for 180 min. The amount of 478 
protein added to each well was 20 µg. (B) SDS-PAGE profile of NaCN incubated with Prolyve (0.3 % (v/v)) for 479 
different durations. Lane 1, Wide range molecular weight marker; Lane 2, NaCN; Lane 3, NaCN incubated with 480 
Prolyve for 5 min; Lane 4, NaCN incubated with Prolyve for 30 min; Lane 5, NaCN incubated with Prolyve for 60 481 
min; Lane 6, NaCN incubated with Prolyve for 90 min; Lane 7, NaCN incubated with Prolyve for 120 min; Lane 8 482 
NaCN incubated with Prolyve for 180 min; Lane 9 NaCN incubated with Prolyve for 240 min. The amount of protein 483 
added to each well was 15 µg. 484 
 485 
Figure 2. Molecular mass distribution profiles of (a) cross -linked pre-hydrolysis sodium caseinate (NaCN) and (b) 486 
cross-linked post-hydrolysis NaCN at different sampling points ■ >10 kDa, ■10-5kDa, ■ 5-2kDa,  <2 kDa) along 487 
with the degree of hydrolysis (DH) of the hydrolysates (- - -).  488 
 489 
Figure 3. Reverse phase (RP) HPLC chromatograms obtained at 214 nm for the different sodium casein ate Prolyve 490 
hydrolysates with and without transglutaminase (TGase) treatments before and after in vitro simulated gastrointestinal 491 
digestion. (a) Prolyve, (b) TGase/Prolyve, (c) Prolyve/TGase. The arrows indicate differences between samples after 492 
incubation with Corolase PP. The arrows at ~ 53 min indicate remained intact casein. 493 
 494 
Figure 4. Change in degree of hydrolysis (DH%) values of non-cross-linked and transglutaminase (TGase) cross -495 
linked hydrolysates of sodium caseinate during simulated gastrointestinal digestion. Prolyve (––), TGase/Prolyve (--496 
-), Prolyve/TGase (─ ─). Mean ± SE (n=3). Different letters denote statistically significant change in DH% at p<0.05.  497 
 498 
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Table 1 683 
Degree of hydrolysis (DH (%)), angiotensin converting enzyme (ACE) and dipeptidyl peptidase -IV (DPP-684 
IV) inhibition of the Prolyve hydrolyzed and transglutaminase (TGase) cross -linked sodium caseinate 685 
(NaCN) hydrolysates before and after simulated gastrointestinal digestion (SGID). 686 
 687 
 688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
Mean ± SD (n=3). For each assay, samples with different letters are significantly different at p<0.05. SGID: 696 
simulated gastrointestinal digestion. IC50 values represent the concentration of hydrolysates that inhibit 50 % 697 
of ACE or DPP-IV activity. 698 
 699 
 700 
 701 
 702 
Sample DH (%) 
ACE 
IC50 (mg protein mL-1) 
DPP-IV 
IC50 (mg protein mL-1) 
 Hydrolysate SGID Hydrolysate SGID Hydrolysate SGID 
Intact NaCN - >10a >10a 
Prolyve 17.46±0.43a 31.4±5.2 b 0.10±0.02b 0.10±0.02b 1.20±0.13 b 1.06±0.54 b 
TGase/Prolyve 16.79±0.77a 31.6±6.2 b 0.17±0.05b 0.14±0.14b 1.05±0.20 b 0.85±0.14 b 
Prolyve/TGase 16.87±0.47 a 33.4±4.2 b 0.15±0.04b 0.23±0.08b 0.97±0.18 b 0.85±0.01 b 
